首页> 外文OA文献 >Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: Identification of novel thiosemicarbazones and therapeutics that prevent this effect
【2h】

Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: Identification of novel thiosemicarbazones and therapeutics that prevent this effect

机译:三氮平,二-2-吡啶基酮-4,4-二甲基-3-硫代氨基脲(Dp44mT)和其他抗癌硫代氨基脲的形成高铁血红蛋白:鉴定新的硫代氨基脲和阻止该效应的疗法

摘要

Thiosemicarbazones are a group of compounds that have received comprehensive investigation as anticancer agents. The antitumor activity of the thiosemicarbazone, 3-amino-2-pyridinecarboxaldehyde thiosemicarbazone (3-AP; triapine), has been extensively assessed in more than 20 phase I and II clinical trials. These studies have demonstrated that 3-AP induces methemoglobin (metHb) formation and hypoxia in patients, limiting its usefulness. Considering this problem, we assessed the mechanism of metHb formation by 3-AP compared with that of more recently developed thiosemicarbazones, including di-2-pyridylketone-4, 4-dimethyl-3-thiosemicarbazone (Dp44mT). This was investigated using intact red blood cells (RBCs), RBC lysates, purified oxyhemoglobin, and a mouse model. The chelation of cellular labile iron with the formation of a redox-active thiosemicarbazone-iron complex was found to be crucial for oxyhemoglobin oxidation. This observation was substantiated using a thiosemicarbazone that cannot ligate iron and also by using the chelator, desferrioxamine, that forms a redox-inactive iron complex. Of significance, cellular copper chelation was not important for metHb generation in contrast to its role in preventing tumor cell proliferation. Administration of Dp44mT to mice catalyzed metHb and cardiac metmyoglobin formation. However, ascorbic acid administered together with the drug in vivo significantly decreased metHb levels, providing a potential therapeutic intervention. Moreover, we demonstrated that the structure of the thiosemicarbazone is of importance in terms of metHb generation, because the DpT analog, di-2-pyridylketone-4-cyclohexyl- 4-methyl-3-thiosemicarbazone (DpC), does not induce metHb generation in vivo. Hence, DpC represents a next-generation thiosemicarbazone that possesses markedly superior properties. This investigation is important for developing more effective thiosemicarbazone treatment regimens.
机译:硫代氨基咔唑是一组已作为抗癌剂进行了全面研究的化合物。在超过20项I和II期临床试验中,已广泛评估了硫代半脲,3-氨基-2-吡啶甲醛硫代半脲(3-AP;三氮平)的抗肿瘤活性。这些研究表明3-AP会引起患者高铁血红蛋白(metHb)的形成和缺氧,从而限制了其用途。考虑到这个问题,我们评估了3-AP与较新开发的硫代半脲酮(包括di-2-pyridylketone-4、4-二甲基-3-thiosemicarbazone(Dp44mT))相比,由3-AP形成metHb的机理。使用完整的红细胞(RBC),RBC裂解物,纯化的氧合血红蛋白和小鼠模型进行了研究。已发现细胞不稳定铁与氧化还原活性的硫代半碳酰胺-铁配合物的螯合对于氧合血红蛋白的氧化至关重要。使用不能结扎铁的硫半脲和使用形成氧化还原非活性铁络合物的螯合剂去铁氧胺证实了该观察结果。重要的是,与其预防肿瘤细胞增殖的作用相反,细胞铜螯合对于metHb的产生并不重要。给小鼠施用Dp44mT催化了metHb和心脏肌红蛋白的形成。但是,体内抗坏血酸与药物一起给药可显着降低metHb水平,从而提供了潜在的治疗干预措施。此外,我们证明了硫代半脲的结构对于metHb的产生很重要,因为DpT类似物二-2-吡啶基酮-4-环己基-4-甲基-3-硫代半碳胺(DpC)不会诱导metHb的产生体内。因此,DpC代表了具有显着优异性能的下一代硫代半碳酰胺。这项研究对于开发更有效的硫半脲治疗方案很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号